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Abstract
A low fat, high carbohydrate diet in combination with regular exercise is the traditional
recommendation for treating diabetes. Compliance with these lifestyle modifications is less than
satisfactory, however, and a high carbohydrate diet raises postprandial plasma glucose and insulin
secretion, thereby increasing risk of CVD, hypertension, dyslipidemia, obesity and diabetes.
Moreover, the current epidemic of diabetes and obesity has been, over the past three decades,
accompanied by a significant decrease in fat consumption and an increase in carbohydrate
consumption. This apparent failure of the traditional diet, from a public health point of view,
indicates that alternative dietary approaches are needed. Because carbohydrate is the major
secretagogue of insulin, some form of carbohydrate restriction is a prima facie candidate for dietary
control of diabetes. Evidence from various randomized controlled trials in recent years has
convinced us that such diets are safe and effective, at least in short-term. These data show low
carbohydrate diets to be comparable or better than traditional low fat high carbohydrate diets for
weight reduction, improvement in the dyslipidemia of diabetes and metabolic syndrome as well as
control of blood pressure, postprandial glycemia and insulin secretion. Furthermore, the ability of
low carbohydrate diets to reduce triglycerides and to increase HDL is of particular importance.
Resistance to such strategies has been due, in part, to equating it with the popular Atkins diet.
However, there are many variations and room for individual physician planning. Some form of low
carbohydrate diet, in combination with exercise, is a viable option for patients with diabetes.
However, the extreme reduction of carbohydrate of popular diets (<30 g/day) cannot be
recommended for a diabetic population at this time without further study. On the other hand, the
dire objections continually raised in the literature appear to have very little scientific basis.
Whereas it is traditional to say that more work needs to be done, the same is true of the assumed
standard low fat diets which have an ambiguous record at best. We see current trends in the
national dietary recommendations as a positive sign and an appropriate move in the right direction.
The case for low carbohydrate diets in diabetes 
management
The epidemic of obesity and diabetes in our society over
the past three decades has been accompanied by a decline
in fat consumption and an apparent attempt to adopt the
traditionally recommended low fat diet [1,2]. According
to the USDA Continuing Survey of Food Intakes by Indi-
viduals (CSFII) [2], the absolute amount of fat and satu-
rated fat consumed has decreased during the obesity
epidemic although there is slight increase for women
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in curbing the obesity pandemic calls into question the
effectiveness and long-term usefulness of such dietary rec-
ommendation and has led to renewed interest in alterna-
tive dietary interventions, notably those recommending
reduced carbohydrate intake. Low fat diets are generally
associated with high carbohydrate intake which in turn is
associated with several metabolic abnormalities [3,4].
These metabolic abnormalities are more pronounced in
the diabetic population, leading to worsening glycemic
control, dyslipidemia and increased inflammation to
name a few. In this review, we discuss the current evidence
for a low carbohydrate diet versus a low fat diet in the
management of people with diabetes, highlighting the
potential role of low carbohydrate diet in ameliorating
various metabolic abnormalities associated with diabetes.
Carbohydrate restriction
It is important to understand that there is no clear cut def-
inition of a low carbohydrate diet in the literature. Various
popular versions recommend carbohydrates intake < 20%
of caloric intake with absolute amounts < 50–60 gm/day,
sometime as low as ≤ 20–30 gm/day at least for short peri-
ods. We distinguish between moderate but significant
reduction in carbohydrates (LoCHO diet) and very low
carbohydrate ketogenic diets (VLCKD) with extreme
reductions (< 20 or 30 g/day) as in the early phase of the
various popular diets [5-7]. The caloric deficit due to car-
bohydrate restriction may be balanced with increased
intake of proteins and fats although the distribution is not
always clear in the application of popular diets and, in at
least two studies, no increase in dietary intake of proteins
or fats was observed presumably due to effect of LoCHO
diet on appetite and satiety [9,12] It is interesting that
despite advocating ad libitum fat and protein intake, a
LoCHO diet may be hypocaloric either by design or by
spontaneous reduction of intake [8-12].
Low carbohydrate diets and weight loss
Data from various studies demonstrate that even a modest
loss of 5–10% of initial body weight may significantly
improve glycemic control, hyperinsulinemia and other
metabolic abnormalities [13,14]. In the Diabetes Preven-
tion Program (DPP) and the Finnish trials, lifestyle inter-
vention including modest weight loss was effective in
preventing the development of diabetes in a high risk
population [15,16]. Weight control, per se, is thus a critical
component for achieving glycemic control, improving
insulin resistance and modifying CVD risk in patients
with diabetes and insulin resistance as well as for diabetes
prevention [14,17].
Traditionally, increased fat intake has been considered as
the main cause for excess energy intake and obesity but
the trends in food intake during the obesity epidemic do
not support this notion [2,18]. While fat intake has
decreased, carbohydrate intake has increased simultane-
ously. This rise in dietary intake of carbohydrates, and
especially highly refined carbohydrate, is a likely culprit in
promoting weight gain and obesity [19].
Weight change is governed by two factors: caloric balance
and macronutrient composition. The first has general
agreement and the expectation is that any hypocaloric
diet, should be effective in achieving weight loss [20]. As
noted above, LoCHO or VLCKD are frequently intention-
ally or spontaneously low calorie. The second considera-
tion, macronutrient composition, is more controversial.
Comparisons of isocaloric diets of different macronutri-
ent composition frequently show no difference in effec-
tiveness but there are several examples where distinct
advantages accrue to one of the diets, usually the low car-
bohydrate arm [21-25].
In a recent study [21], for example, significantly greater
weight loss was demonstrated with low carbohydrate
intervention (< 10% calories from carbohydrates) despite
higher caloric intake (1855 kcal/day) compared to high
carbohydrate (60% calories from carbohydrates) with
lower caloric intake (1562 kcal/day). There are several
other reports indicating metabolic advantage in low car-
bohydrate diets over short term (3–6 months)
[8,10,11,26-28]. Significant reductions in fat mass includ-
ing truncal fat, which is a marker for visceral obesity, have
been demonstrated in many studies [9,11,26,29]. A recent
report [30] indicates that the effect will be seen primarily
in subjects with insulin resistance. The association of insu-
lin resistance with diabetes makes this of great impor-
tance.
Although the exact mechanism for this metabolic advan-
tage is unknown, it is has been attributed to greater ther-
mogenic effect of proteins in the face of increased demand
for gluconeogenesis, increased futile cycling and increase
in mitochondrial uncoupling [21,22,24]. Despite evi-
dence suggesting more weight loss with isocaloric low car-
bohydrate diets, the issue of metabolic inefficiency with
low carbohydrate dietary interventions is controversial
and still not universally accepted.
The data for long term effectiveness of LoCHO diet is lim-
ited to studies with small sample size, poor adherence to
dietary assignment in all dietary groups and inability to
control the dietary carbohydrate amount over longer
duration, making it difficult to demonstrate an apprecia-
ble difference between the dietary interventions. It is
important to stress, however, that the same disclaimer
must be made for low fat diets. Whereas calorie reduction
by any means will lead to weight loss, the only compari-
sons of low fat diets are exactly the ones with low carbo-Page 2 of 9
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low fat diets have great compliance or long term effects
that can be attributed to the particular regimen [31]. Two
of the low carbohydrate-low fat comparisons were contin-
ued for 1 year [8,27]. It is frequently cited that the differ-
ence in weight loss between the LoCHO diet and low fat
diet was not statistically significant after one year but it
should be pointed out that in these studies, participants
had the freedom to increase the carbohydrate content of
the diet over longer duration and it is reasonable to say
that as carbohydrate is added back to the diet, its effective-
ness wanes. For example, in the study by Foster et al. [8],
there was no significant difference in the urinary ketone
levels between the two study groups after 3 months, sug-
gesting inadequate carbohydrate restriction during the
later part of the study which would contribute to the sim-
ilarity in various parameters between the groups. In addi-
tion, the authors of these studies included subjects who
had dropped out of the study. This method, justified
under the name "intention to treat analysis" obscures the
information in the study and has the effect of making the
more effective diet look worse. In another recent study
[32] comparing the effects of four popular diets including
LoCHO diet and low fat diet, there were no significant dif-
ferences in weight loss in the different groups at the end of
1 year. However, this study also had the shortcomings of
the above studies, including small sample size (40 sub-
jects in each group) and poor adherence in all the groups
(30–60% dropouts). The LoCHO diet group also failed to
reach carbohydrate reduction goal with carbohydrate
intake of 190 gm/day at 6 months and 12 months as com-
pared to baseline of 239 gm/day. Hence, it is not surpris-
ing that weight loss was not significantly different in
LoCHO diet group. What is encouraging is that despite
such marginal carbohydrate restriction in the LoCHO
group, this group was able to achieve a modest weight loss
that was comparable to the other diet groups, while main-
taining a greater improvement in lipid profile suggesting
that even minimal carbohydrate restriction may have ben-
eficial effects in term of weight loss and might be offered
to those at high risk who fail to lose weight with tradi-
tional low fat diet.
Low carbohydrate diet and glycemic control
Diets containing 50–60% calories from carbohydrates
have been the standard recommendation for patients with
type 2 diabetes and metabolic syndrome [33-35]. How-
ever, evidence from several epidemiological studies such
as the Nurses Health Study [36] and Health Professional
Follow-Up Study [37] has linked dietary carbohydrate
intake (measured as glycemic load) with risk of type 2 dia-
betes and CVD. In the Framingham Offspring Study [38],
high glycemic index and glycemic loads were positively
associated with metabolic syndrome. Prospective cohort
studies have also linked carbohydrates with development
of diabetes [39,40]. Compelling evidence from clinical
and metabolic studies demonstrate worsening of glycemic
control and dyslipidemia in diabetics with high carbohy-
drate diet [3,4,41,42] whereas low carbohydrate diet may
reverse these serious metabolic abnormalities [10,27,43-
46]
Carbohydrates are the major insulin secretagogues [47]
and glycemic control in diabetic subjects is greatly influ-
enced by dietary carbohydrate content. In fact, before the
discovery of insulin, dietary carbohydrate restriction was
the recommended treatment for diabetes management
[48]. While subjects with type 1 diabetes are generally
counseled to count dietary carbohydrates and adjust insu-
lin dose accordingly [35], the concept of carbohydrate
restriction in type 2 diabetes is not adequately empha-
sized. High carbohydrate intake is generally recom-
mended, resulting in suboptimal glycemic control and
lipoprotein profile, gradually increasing insulin and/or
oral hypoglycemic medication requirement and weight
gain. On the other hand, restriction of dietary carbohy-
drates is associated with improvement in glycemic control
and other parameters of insulin resistance including body
mass and lipid profile[8-10,43,45].
In the analysis of effects of macronutrient composition of
diet on glycemic control, it is essential to differentiate the
effect of carbohydrate restriction from that of weight loss
so as to determine if the diet has beneficial effect on glyc-
emic control independent of weight loss. This has been
clarified by short term study in weight stable diabetic
patients where carbohydrate restriction resulted in signif-
icant decrease (8.1% to 7.3%, p < 0.05) in glycosylated
hemoglobin (HbA1c) compared to a high carbohydrate
control diet [46]. In another study by the same group [45]
in 8 diabetic men in a randomized 5-week cross over
design with a 5-week wash out period, even larger benefi-
cial effects on glycemic control were observed with low
carbohydrate intervention (carbohydrate 20%, protein
30% and fat 50%) compared to control diet (carbohy-
drate 55%, protein 15% and fat 30%). The low carbohy-
drate diet had lower HbA1c (7.6 % ± 0.3), glucose levels
and insulin levels compared to high carbohydrate group
(HbA1c 9.8 % ± 0.5) despite similar weight loss with both
diets. These data demonstrate that the benefits of low car-
bohydrate diet on glycemic control are independent of
weight loss and are primarily due to carbohydrate reduc-
tion.
In a recent study [43] on obese diabetic subjects, a LoCHO
diet (20% carbohydrates) was associated with a signifi-
cant reduction in body weight, BMI, fasting blood glucose
and HbA1C at 6 months compared to the high carbohy-
drate group (60% carbohydrates). Significant decreases in
insulin and hypoglycemic medication requirement werePage 3 of 9
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improvements in glycemic control were also reported by
Boden et al. [9]. The study of Samaha et al. [10] also
reported a decrease in mean fasting plasma glucose (FPG)
levels in diabetic subjects with low carbohydrate diet com-
pared to low fat diet group. The decrease in FPG correlated
with the weight loss in this study though the one year data
did not show any significant difference, likely due to ina-
bility to achieve target carbohydrate intake in the LoCHO
diet group and to the significant number of dropouts
affecting the power of the study to measure a statistically
significant difference.
To summarize, the effect of LoCHO diet on glycemic con-
trol was significantly greater and occurred independent of
weight loss in those studies that were able to achieve and
maintain adequate carbohydrate restriction. In other stud-
ies, the effect on glycemic control was modest and propor-
tional to the weight loss, and at least comparable to that
seen with low fat diet.
In conclusion, low carbohydrate diet is associated with
significant improvement in glycemic control and has the
potential for reduction in need for exogenous insulin or
oral hypoglycemic medications. Increased monounsatu-
rated fatty acid (MUFA) intake and reduction of saturated
fat intake may further improve the insulin sensitivity and
glycemic control with low carbohydrate diet.
Low carbohydrate diet and postprandial 
hyperglycemia
Postprandial hyperglycemia is a risk factor for CVD, par-
ticularly in diabetic patients [49-51]. Many studies includ-
ing the Nurses Health Study [36] have suggested a link
between dietary carbohydrates (measured in terms of gly-
cemic load) and CVD risk. Furthermore, control of post-
prandial hyperglycemia has been shown to provide
cardiovascular benefits, and to contribute to the overall
decrease of hemoglobin A1c, something that has been
clearly shown to reduce microvascular disease in both
type 1 and type 2 diabetes [52,53]. Dietary carbohydrates
are the major determinants of postprandial glucose levels
[17,47,54] and LoCHO diets have been reported to lower
postprandial glucose levels directly and indirectly by way
of weight loss and may have beneficial effects on CVD risk
factors [4,14]. Significant reductions in postprandial
plasma glucose and plasma insulin levels with LoCHO
diet have been demonstrated in many studies [4,9,42,55].
Furthermore, control of postprandial hyperglycemia with
acarbose, an α-glucosidase inhibitor, has been demon-
strated to significantly decrease the risk of diabetes in
patients with impaired glucose tolerance [56,57].
Low Carbohydrate diet and Dyslipidemia
Type 2 diabetes and metabolic syndrome are commonly
associated with atherogenic dyslipidemia, characterized
by elevated triglycerides (TG) levels and low HDL levels
[17,58]. Additionally, qualitative changes in LDL choles-
terol may be present in the form of small, dense LDL par-
ticles which are more atherogenic and may be associated
with higher risk of CVD [58-60]. Evidence from various
studies has confirmed that LDL, HDL and triglycerides are
independent predictors of CVD [17,61-63]. Since nearly
75 % of diabetics die of heart disease, control of diabetic
dyslipidemia is an important strategy in the primary pre-
vention of CVD and a low fat high carbohydrate diet has
been the standard recommendation from various health
organizations to achieve this target [33-35]. A mounting
body of evidence however, has demonstrated that the tra-
ditional low fat high carbohydrate diet is associated with
elevated triglyceride and low HDL cholesterol levels and
may worsen the dyslipidemia of type 2 diabetes and met-
abolic syndrome [3,10,25,27,28]. Reduction in dietary
intake of fat is frequently associated with increased intake
of carbohydrates and leads to carbohydrate induced
hypertriglyceridemia (HPTG) [64-69]. This phenomenon
has been observed in subjects consuming high carbohy-
drate low fat diets for as few as 5 days, with replacement
of as little as 10% fat with carbohydrate and with dietary
fat intake of as much as 30% of energy [64,65]. Decreasing
fat without increasing carbohydrate does not appear to
elevate triglycerides, thereby suggesting that addition of
carbohydrates and not reduction in fat is responsible for
this HPTG seen with high carbohydrate low fat diets.
Though the exact mechanism for carbohydrate induced
HPTG has not been clearly elucidated, both increase in TG
synthesis and decrease in fractional TG clearance have
been demonstrated [64-66] with a possible contribution
from increased hepatic de novo fatty acid synthesis [64,67].
A number of factors influence the occurrence of carbohy-
drate induced HPTG and these include high BMI (>28 kg/
m2), insulin resistance, post menopausal state, and
genetic factors [64,65]. Diabetic, insulin resistant and
obese subjects are thus at even higher risk. In addition,
type and form of carbohydrates, particularly high sugar/
starch ratio also contribute to carbohydrate induced
HPTG [64]. Conversely, LoCHO diets have been consist-
ently demonstrated to lower triglycerides and increase
HDL [8-11,26-28]. Even the studies which failed to show
significant differences in weight loss between LoCHO diet
and low fat diets after one year [8,27] demonstrated sig-
nificant reduction in TG and an increase in HDL with the
LoCHO diet despite inability of subjects to achieve target
carbohydrate intake. This result suggests that the improve-
ment in TG is not only independent of weight loss but,
again, even modest reduction in carbohydrate intake may
have significant benefits on lipids. Significant clinical
implications comes from the VA-HIT study [61], where aPage 4 of 9
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were associated with notable improvement in CVD mor-
tality.
Though weight loss per se, in combination with increased
physical activity, is usually associated with an increase in
HDL cholesterol and decreases in triglyceride and LDL
cholesterol concentration, the beneficial effects on lipids
of the caloric reduction in LoCHO diets appear to be sec-
ondary or additive to carbohydrate restriction and are
seen even after adjusting for amount of weight loss[27].
A low fat diet, in the presence of weight loss is effective in
lowering serum LDL cholesterol. On the other hand, such
a regimen decreases HDL cholesterol without a significant
increase in LDL size to less atherogenic form [70]. Emerg-
ing evidence suggests that LoCHO diets may actually have
beneficial effects on LDL cholesterol by decreasing LDL
particle concentration and increasing LDL size to less
atherogenic form [25,28,70-73].
In summary, a low carbohydrate diet may be more effec-
tive than a low fat diet at improving the characteristic dys-
lipidemia associated with diabetes, namely high TG, low
HDL and increased small dense LDL particles [70].
Low carbohydrate diet and insulin resistance
LoCHO diets have been reported to have beneficial effect
on hyperinsulinemia seen in type 2 diabetes and insulin
resistance [8-10,45]. The data is, however, limited by few
studies with small number of diabetic subjects and differ-
ences in method of measuring insulin sensitivity in vari-
ous studies. Boden et al. demonstrated significant
improvement in insulin sensitivity, up to 75%, with a low
carbohydrate diet as measured by euglycemic hyperin-
sulinemic clamp method [9]. In another study [29], sig-
nificant decreases in insulin to glucose ratio were seen in
the LoCHO group suggesting improved insulin sensitiv-
ity, especially in subjects with insulin resistance and
higher baseline insulin levels. Similar improvement in
insulin sensitivity was reported by Gannon, et al [45]. In
the studies by Samaha et al. [10] and by Foster et al [8],
carbohydrate restriction was associated with a significant
increase in insulin sensitivity at 6 months (measured only
in non-diabetic subjects) although the difference between
the low fat and low carbohydrate groups was not statisti-
cally significant at 1 year [27]. Notably, again, these stud-
ies allowed increasing carbohydrate in the LoCHO group
with time thereby reducing the effectiveness of this group.
Reduction in visceral obesity and omental fat may be
important since LoCHO diets have been reported to
reduce fat mass including truncal fat over long term in
many studies [11,21,26,29]. Finally, a recent study
showed that effectiveness of low carbohydrate diets was
more visible in a group that was insulin-resistant [30].
Low carbohydrate diet and hypertension
Hypertension is a common co-morbidity in type 2 diabe-
tes affecting 20–60% of the diabetic population[74] and
contributes significantly to CVD risk. Hypertension is a
major predictor of increased macrovascular and microvas-
cular complications of diabetes [17,52,53,75]. Hyperten-
sion in diabetes is usually a component of metabolic
syndrome and is related to carotid wall atherosclerotic
lesions and angina [17]. A number of studies in animals
[76] and one in humans [77] have linked sugar intake
with hypertension. Direct correlation between plasma
insulin levels and blood pressure levels has been demon-
strated and there is evidence to suggest a causal relation-
ship between insulin resistance with resultant
hyperinsulinemia and hypertension [17]. The proposed
mechanisms include renal sodium retention, vascular
smooth muscle proliferation, sympathetic stimulation
and vascular hyperreactivity [17].
The role of macronutrient composition of diet on blood
pressure has not been adequately studied, though any die-
tary intervention effective for improving insulin resistance
should also have beneficial effects on hypertension. The
relationship between hypertension and weight loss is well
documented [13,74] and weight loss of 1 kilogram has
been reported to decrease mean arterial blood pressure by
approximately 1 mm Hg. Low carbohydrate diets have
been reported to lower blood pressure by causing weight
loss and improving the insulin sensitivity, though the
magnitude of effect on blood pressure has been small (1–
10 mm Hg) in most studies [8,10,29] and comparable to
that seen with low fat diet.
Low carbohydrate diet and inflammation
Insulin resistance is the predominant mechanism associ-
ated with type 2 diabetes and is also central to the patho-
genesis of metabolic syndrome [17]. Abnormal levels of
inflammatory markers such as C-reactive protein and pro-
thrombotic markers like plasminogen activator inhibitor-
1 (PAI-1) have been reported in insulin resistant subjects
[17] and may contribute to the increased CVD events in
this population in combination with dyslipidemia and
hypertension [17]. High carbohydrate diets, by increasing
the insulin secretion, may worsen insulin resistance in
diabetic patients and increase the inflammatory and pro-
thrombotic tendencies in this patient population. The
effect of low carbohydrate diet on various inflammatory
and pro-coagulant markers is not well studied although
these markers have been shown to improve with weight
loss in general [13,78-80]. Therefore, any diet that causes
effective weight loss should be able to cause a decrease in
these inflammatory markers and such decreases in CRP
[32,70] and PAI-1 levels [29] have been demonstrated
with low carbohydrate diet. However, these data are lim-
ited, and long term studies are needed to confirm thesePage 5 of 9
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on the CVD end points with low carbohydrate diet.
The case for a low carbohydrate diet
Despite the growing popularity of LoCHO diets and
emerging evidence for its effectiveness, there is reluctance
among physicians to prescribe it, even in high risk popu-
lations who have failed to benefit from traditional low fat
diets. The possible explanation is that although carbohy-
drate restriction can be implemented in any number of
ways, it is generally identified with the popular Atkins diet
for which health organizations have great hostility, focus-
ing on a literal interpretation of permission for unlimited
fat intake. Health organizations have been slow to adapt
carbohydrate restricted diets even in the face clear evi-
dence for the adverse effects of high carbohydrate intake
exacerbating the metabolic abnormalities in diabetes and
insulin resistant states. Similarly, we have previously
pointed out the general tendency to downplay the benefi-
cial effects of LoCHO diets by individual researchers [81].
Weight loss associated with LoCHO diets has been contin-
ually attributed to alteration in body water [82,83].
Numerous studies have shown that, although initial alter-
ation in body water with carbohydrate restriction is possi-
ble, the new equilibrium state is achieved in 2–3 weeks,
followed by active loss of fat mass [8,20,21,26,29,73]. In
fact, a recent study [9] showed mean energy intake
decreased from 3111 kcal/day to 2164 kcal/day on a low
carbohydrate diet with mean energy deficit of 1027 kcal/
day. The weight loss was proportional to mean energy def-
icit and was explained by loss of fat mass, not water loss.
Another concern that has been voiced is unlimited fat
intake as part of low carbohydrate diet may cause weight
gain and obesity over the long term. [34,47]. Again, this is
not substantiated with evidence and the objection is not
valid for the many reasons. Firstly, there is evidence that
type of fat is much more important than total fat intake
[84]. Whereas saturated fats have been linked with
increased CVD risk, the use MUFA and PUFA have been
inversely associated with CVD risk [84]. Therefore, if car-
bohydrate restriction is used with increase in unsaturated
fats, the benefits may be even more and indeed, improve-
ment in glycemic control, insulin sensitivity and dyslipi-
demia including reduction in LDL cholesterol has been
demonstrated with such dietary intervention in several
clinical and metabolic studies[3,41,85].
Another major reason for lack of enthusiasm for LoCHO
diet is misinterpretation of data provided by studies up to
1 year duration. The general view is that the LoCHO diet
are not more effective than low fat high carbohydrate diet
in terms of weight loss in studies up to 1 year duration
despite impressive short term weight loss [8,27,32]. How-
ever, as we mentioned earlier, considering that the data is
already biased in favor of low fat diet, the lack of signifi-
cance between the diet groups at 12 months still proves
the superiority of LoCHO diet as it was able to achieve
similar or better weight loss despite less than desired car-
bohydrate restriction. Again, even a marginal decrease in
carbohydrate intake may be beneficial in terms of weight
loss and lipid benefits. The overall dietary compliance was
a major problem in all these studies but was generally
comparable between the two diet groups. A lot has been
said about nutritional inadequacy due to mineral, electro-
lytes and vitamin deficiencies and the adverse health
effects of LoCHO diets on renal and skeletal mass [34].
On the other hand, there is evidence that increasing sugar
intake adds empty calories by displacement of whole
foods and has been associated with a linear decrease in
intake of many essential nutrients as demonstrated by
Bogalusa Heart Study [86]. Since carbohydrate restriction
may limit some micronutrient and fiber intake, the popu-
lar versions of LoCHO diets recommend mandatory
intake of multivitamins including calcium, fish oil and
fiber supplements. The renal and skeletal effects remain
theoretical concerns not substantiated with evidence.
Studies up to 1 year have not shown any adverse effects on
renal function or skeletal mass. Also, adequate intake of
calcium and vitamin D supplements as routinely recom-
mended with LoCHO diet should help preserve skeletal
mass along with prescription of increased physical activity
which should be offered to all irrespective of the dietary
macronutrient composition. There have been some
reports of increase blood urea nitrogen without any
decrease in glomerular filtration which are related to
increase in protein intake and do not represent renal
insufficiency. A theoretically increased risk of renal stones
has been claimed with LoCHO diet but again, there is no
evidence for such claims and nothing that adequate
hydration could not correct. However, in the absence of
definite evidence, recommendations must be based on
professional judgment. Although proponents of LoCHO
diets recommend ad libitum fat intake, we do not endorse
this and instead favor use of MUFA and PUFA which have
been demonstrated in various studies to reduce the risk of
CVD [3,4,41,84]. A final irony is the report that physicians
frequently choose LoCHO diets for themselves while rec-
ommending low fat for their patients[87].
Where we stand
Based on our examination of current evidence, we find
concerns about LoCHO diets to be unsubstantiated and
we see no problem in recommending them, at least as a
means of caloric reduction. Of course, reducing calories
by removing fat is universally agreed on as beneficial but
the real question is which should be the priority. We
believe from the evidence presented here that replacing fat
with carbohydrate is deleterious and caloric restriction
should be carried out by removing carbohydrate in prefer-Page 6 of 9
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ommended by various popular LoCHO diets, we
routinely remind our patients to avoid excess calorie
intake. Also, because restriction of carbohydrates may
limit intake of certain vitamins and minerals, supplemen-
tation with multivitamin supplements including calcium
is a usual recommendation with LoCHO diets. Since high
fiber intake has been inversely associated with CVD
[37,88], patients should be encouraged to increase fiber
intake and should receive fiber supplements if necessary.
As for VLCKD where carbohydrate restriction is targeted to
20–30 gm/day at least for two weeks, we consider this an
extreme change for most people and therefore we would
not recommend it without substantial evidence from clin-
ical trials is provided as to the benefits of this extreme die-
tary intervention.
Low Carbohydrate diet and the current 
guidelines for diabetes management
Traditionally, a low fat high carbohydrate diet containing
55–70 % carbohydrates, 15–20% proteins and 20–30%
fats has been recommended by various health organiza-
tions [33-35] for subjects at high risk of CVD including
those with diabetes and metabolic syndrome. Despite
accumulating evidence suggesting deleterious effects of
high carbohydrate diet and potential benefits of carbohy-
drate restriction, LoCHO diet have met with increased
resistance and have not been accorded its deserved place
in various treatment guidelines.
The current position statement of the American Diabetes
Association (ADA), however, recognizes the importance
of amount of dietary carbohydrates: "With regard to the gly-
cemic effects of carbohydrates, the total amount of carbohydrate
in meals or snacks is more important than the source or the
type". This organization also agrees with role of carbohy-
drate restriction as stated "In weight maintaining diets for
type 2 diabetes, replacing carbohydrates with monounsaturated
fats reduces post prandial glycemia and triglyceridemia" and
recommends that "carbohydrates and monounsaturated fat
together should provide 60–70% of the energy intake and the
relative contributions of carbohydrate and monounsaturated
fats to energy intake should be individualized". This can be
considered as a nod of approval for carbohydrate restric-
tion though no specific recommendation has been made.
Furthermore, the ADA's recommendation of individuali-
zation according to patient's risk may provide the much
needed flexibility for adjusting the carbohydrate content
according to the patient's requirement [47]. This gradual
adoption of carbohydrate restriction is also reflected by a
recent statement from ADA limiting dietary carbohydrate
intake to provide 45–65% of the calories [47] which is less
than previously recommended.
Conclusion
Low carbohydrate diet compares more favorably, at least
over the short term, to traditional low fat for improving
glycemic control, insulin sensitivity and dyslipidemia of
diabetes with reduction in triglycerides, increase in HDL
cholesterol and modification of LDL to less atherogenic
form. The need of the hour is to accept the benefits of car-
bohydrate restriction with reservation and to establish
guidelines for its use, especially emphasizing use of mono
and polyunsaturated fats as the way to achieve caloric bal-
ance since these have been inversely linked with CVD risk
in various studies. In the mean time, clinical trials need to
be conducted using graded levels of carbohydrate restric-
tion and fat intake, with special emphasis on unsaturated
fats, to examine their effects of on weight loss, glycemic
control, insulin resistance and CVD risk. This is to resolve
the present controversy about optimal dietary option for
patients with diabetes.
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